Key Takeaways
- New York’s cannabis market generated over $4.1 billion in sales since legalization in December 2022, but this is cumulative over four years, not annual revenue.
- California leads the U.S. cannabis market with annual sales around $4.5 to $5 billion, making New York’s total appear smaller by comparison.
- New York ranks fifth among U.S. cannabis markets, trailing behind states with longer-established programs, like California and Michigan.
- Challenges like administrative delays and a large unregulated market hinder New York’s cannabis growth, despite climbing legal sales.
- The state continues to address issues with unlicensed shops and licensing backlogs to sustain market momentum.
New York’s cannabis program is growing, and growing fast. But the headlines touting $4 billion in sales deserve some context before anyone declares the state a cannabis powerhouse. Here’s what the number actually represents, how it measures up against the biggest of legal cannabis programs in the US, and why New York’s road to this point has been bumpier than most states that legalized recreational marijuana before it.
What Does New York’s $4 Billion Cannabis Milestone Actually Mean?
The $4.1 billion figure comes from the New York Office of Cannabis Management (OCM), which reported during its October 2026 Cannabis Control Board meeting that licensees have generated that total in retail sales since the state’s adult-use program began in December 2022. That’s a cumulative number covering roughly four years of operation, not a single year of revenue.
Earlier in 2026, Gov. Kathy Hochul’s office marked the five-year anniversary of the Marihuana Regulation and Taxation Act (MRTA) by announcing $3.3 billion in total sales and more than 600 licensed dispensaries. By September 2026, that count had grown to 1,039 retail licenses issued and 712 stores open for business, according to OCM’s quarterly retail market update.
Sales have also been climbing on a quarterly basis. New York brought in $512.6 million in retail sales during the third quarter of 2026 alone, bringing year-to-date sales to $1.41 billion. Daily sales hit a record high of $5.14 million in April 2026, up from $4.4 million in January of that year. The trajectory is positive. The scale, though, still has a long way to go before New York challenges the country’s biggest markets.
How Does New York’s Cannabis Market Compare to California’s?
California remains the largest legal cannabis market in the country by a wide margin. According to the California Department of Cannabis Control and the state’s Department of Tax and Fee Administration, legal cannabis sales in California average between $4.5 billion and $5 billion annually, with retail revenue peaking at $5.35 billion in 2021. Recent annual totals have settled closer to $4.97 billion, with the market consistently moving $1.1 billion to $1.25 billion in retail sales every quarter.
California’s tax haul tells a similar story of scale. The state has collected more than $8.4 billion in cannabis tax revenue since legal sales began in January 2018, split between a 15% excise tax and standard sales tax.
Put side by side, New York’s entire four-year cumulative total of $4.1 billion is roughly what California generates in a single year. That’s not a knock on New York. It’s a reflection of California’s head start (legal sales began there in 2018, four years before New York’s launch) and the sheer size of its consumer base. California also still battles an unregulated market that accounts for 40% to 50% of total cannabis transactions statewide, so even the country’s largest legal market has room to grow into its full potential.
Where Does New York Rank Among the Country’s Cannabis Markets?
By most industry estimates, New York currently sits around fifth place among U.S. cannabis markets when ranked by sales volume. California holds the top spot, and Michigan has emerged as the second-largest adult-use marijuana market in the country, with retailers reporting about $3.17 billion in sales during 2025 alone, according to the Michigan Cannabis Regulatory Agency.
Rounding out the states ahead of New York are markets with longer operating histories and denser retail networks, plus at least one state whose ranking comes largely from a long-established medical cannabis program rather than adult-use sales. That distinction matters. New York’s adult-use program is still in its early growth phase, while some of the states ahead of it have had years, or in some cases a decade or more, to build out licensed retail infrastructure and customer habits.
New York’s retail density is actually competitive for a newer program. The state has about 5.4 dispensaries for every 100,000 residents, which puts it ahead of Illinois, Nevada, and California on a per-capita basis, according to OCM’s Q3 2026 retail monitoring report. States like Oregon and Colorado remain well ahead of New York in retail saturation, a dynamic that regulators have flagged as a cautionary tale about store growth outpacing demand.
Why Was New York’s Recreational Cannabis Rollout So Rocky?
New York’s path to a functioning adult-use market has been anything but smooth. The state’s Conditional Adult-Use Retail Dispensary (CAURD) program, designed to give priority licensing to people harmed by cannabis prohibition, got tied up in legal challenges and administrative delays almost immediately after launch. Many conditional licenses took months, sometimes years, to convert into operating storefronts.
Public comments at OCM’s own board meetings reflect the frustration. Applicants from the state’s original December 2023 licensing queue described waiting nearly three years for a decision, while others reported losing access to their application accounts mid-review and getting denied over what they say were administrative errors outside their control.
Capital access has been another persistent obstacle, particularly for social equity applicants. A state loan program run through the Dormitory Authority was quietly halted in 2024 after critics alleged it had become predatory, leaving many social equity licensees without the funding promised under the MRTA to actually open their doors. Operators who spoke at recent board meetings described having licenses in hand but no realistic way to finance a buildout, a gap that undercuts the equity goals the program was built around.
Is New York’s Unregulated Cannabis Market Still a Problem in 2026?
Yes, and it’s a big one. Even as licensed dispensaries report record sales, unlicensed shops continue to undercut the legal market on price and convenience. One cannabis retailer in Queens told the New York Post that while legal daily sales reached $5 million for the first time in April 2026, unregulated sales could be running as high as $50 million a day, roughly ten times the legal figure, with some illegal operators even advertising through Meta and Google.
The state has ramped up enforcement in response. According to OCM, 2025 brought 2,017 enforcement actions statewide, resulting in more than $20 million in unregulated cannabis seized and 579 unlicensed storefronts shut down. New York City Sheriff’s deputies and the NYPD have padlocked more than 1,650 unregulated shops to date. Despite that activity, operators continue to report that illegal delivery services and pop-up shops reopen quickly after closures, often within the same neighborhood.
The high tax burden on legal operators, combined with licensing and compliance costs, creates a price gap that keeps pushing some consumers toward unlicensed sellers. It’s a challenge California, with its own unregulated market accounting for nearly half of all cannabis transactions, knows well too.
Where New York’s Cannabis Market Goes From Here
New York’s cannabis industry is still finding its footing, and the numbers reflect a market in transition rather than one that has fully matured. The state has built real momentum: licensed sales are climbing, retail density is improving, and regulators are actively working through compliance and licensing backlogs. At the same time, operators and applicants continue to raise legitimate concerns about capital access, processing delays, and an unregulated market that hasn’t gone away.
The comparison to California isn’t meant to diminish what New York has built. It’s a reminder that a mature, multi-billion-dollar annual cannabis market takes years of consistent retail growth, enforcement, and consumer trust to establish. New York crossed $4 billion in cumulative sales in roughly four years. Whether it can sustain that growth rate and close the gap with the country’s largest markets will depend heavily on how quickly the state resolves its licensing backlog and gets a handle on the unlicensed shops still competing for the same customers.
Frequently Asked Questions
New York’s licensed cannabis retailers have generated more than $4.1 billion in total sales since adult-use sales began in December 2022, according to figures presented at the October 2026 Cannabis Control Board meeting.
No. California’s cannabis market generates between $4.5 billion and $5 billion in sales every year, while New York’s $4.1 billion figure represents nearly four years of cumulative sales. California remains the largest legal cannabis market in the country.
New York is generally considered the fifth-largest cannabis market in the country, behind California, Michigan, and other states with longer-established adult-use or medical programs.
New York’s CAURD licensing program faced lawsuits, administrative delays, and capital access issues for social equity applicants, which slowed the pace of dispensary openings well behind the original timeline.
Yes. Despite record legal sales, industry estimates suggest unregulated cannabis sales in New York City could be as much as ten times higher than licensed sales, even as the state ramps up enforcement against unlicensed shops.
